International Journal of Biological and Pharmaceutical Sciences Archive

ISSN: 0799-6616 (Online)

Journal homepage: https://ijbpsa.com/

(Review Article)

The evolving threat of antimicrobial resistance in surgical site infections: Mechanisms, epidemiology, and innovative mitigation strategies

Barnabas Ogheneruru Okposio [1, *], Tamasanni Salawu Omeiza [2], Kehinde Dorcas Ogunleye [3], Blessing Temitope Ayanwunmi [4], Chizaram Anselm Onyeaghala [5], Ikenna Kenneth Maduike [6] and Christopher Onyema Ugwu [7]

[1] *Department of Pharmacology, Delta State University, Abraka, Nigeria.*
[2] *Department of Surgery, Kogi State Specialist Hospital, Lokoja Nigeria.*
[3] *Department of Pharmacy, University of Ilorin, Ilorin, Nigeria.*
[4] *Department of Health Education, University of Ilorin, Ilorin, Nigeria.*
[5] *Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.*
[6] *Department of Biotechnology, School of Life Sciences, University of Bedfordshire, United Kingdom.*
[7] *Department of Veterinary medicine, University of Nigeria, Nsukka.*

International Journal of Biological and Pharmaceutical Sciences Archive, 2025, 10(01), 246-271

Publication history: Received on 15 August 2025; revised on 22 September 2025; accepted on 24 September 2025

Article DOI: https://doi.org/10.53771/ijbpsa.2025.10.1.0072

Abstract

The relentless rise of antimicrobial resistance (AMR) in surgical site infections (SSIs) threatens the foundation of modern surgery, escalating patient morbidity, mortality, and healthcare costs while challenging the efficacy of conventional antibiotic therapies. This review delves into the intricate mechanisms driving AMR, including genetic mutations, biofilm formation, and efflux pumps, which empower pathogens like methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative bacteria to evade treatment. It unveils the alarming global epidemiology of resistant SSIs, with low- and middle-income countries disproportionately burdened due to limited diagnostic and infection control resources. The paper confronts the formidable challenges of delayed diagnostics, dwindling antibiotic efficacy, and inconsistent stewardship, while spotlighting innovative mitigation strategies that redefine SSI management. Tailored antimicrobial prophylaxis, non-antibiotic approaches like bacteriophage therapy and nanotechnology, advanced infection prevention techniques, and novel pharmacological agents offer hope in combating resistance. By weaving together the expertise of surgeons, medical professionals, and pharmacists, bolstered by robust policy and education, this review charts a path toward sustainable solutions. It calls for global collaboration to curb the AMR crisis, ensuring that surgical interventions remain safe and effective for future generations.

Keywords: Antimicrobial Resistance; Surgical Site Infections; Multidrug-Resistant Pathogens; Antibiotic Prophylaxis; Infection Prevention; Bacteriophage Therapy; Nanotechnology; Interdisciplinary Collaboration

1. Introduction

Surgical site infections (SSIs) represent a significant challenge in modern healthcare, contributing to increased morbidity, prolonged hospital stays, and substantial economic burdens. The rise of antimicrobial resistance (AMR) has exacerbated this issue, rendering conventional antibiotic therapies less effective and complicating surgical outcomes. This review explores the intersection of medicine, surgery, and pharmacy to address the evolving threat of AMR in SSIs, focusing on its mechanisms, epidemiology, and innovative mitigation strategies. By integrating interdisciplinary perspectives, this paper aims to provide a comprehensive framework for understanding and combating AMR in surgical settings.

* Corresponding author: Barnabas Ogheneruru Okposio; Email: okgreat1950@gmail.com

1.1. Overview of Surgical Site Infections and Their Impact on Patient Outcomes

Surgical site infections are postoperative complications that occur at the site of surgical intervention, typically within 30 days of surgery or up to 90 days for implant-related procedures. According to Anderson et al. [1], SSIs account for approximately 20% of healthcare-associated infections in the United States, with incidence rates ranging from 2–5% for most surgical procedures. These infections are classified as superficial, deep incisional, or organ/space infections, each presenting unique diagnostic and therapeutic challenges. The primary pathogens implicated include *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*, with resistant strains such as methicillin-resistant *S. aureus* (MRSA) increasingly prevalent. The clinical impact of SSIs is profound, often leading to delayed wound healing, secondary infections, and, in severe cases, sepsis or death.

The impact of SSIs extends beyond clinical outcomes to affect patient quality of life and healthcare systems. Findings from Badia et al. [2] indicate that SSIs can extend hospital stays by an average of 7–11 days, significantly increasing healthcare costs. For instance, a study by Zimlichman et al. [3] estimated that SSIs contribute to an additional $3.5–$10 billion annually in healthcare expenditures in the United States alone. Patients with SSIs often experience physical and psychological distress, including pain, prolonged recovery periods, and anxiety related to treatment failures. In developing countries, where access to advanced diagnostics and treatments is limited, SSIs pose an even greater threat, often resulting in higher mortality rates. To provide a structured overview of SSI classifications and their multifaceted impacts, Table 1 summarizes key types, associated pathogens, incidence rates, clinical and economic burdens, and supporting references.

The emergence of AMR has further complicated SSI management. Resistant pathogens reduce the efficacy of prophylactic and therapeutic antibiotics, leading to higher rates of treatment failure. According to Allegranzi et al. [4], the global burden of SSIs is disproportionately high in low- and middle-income countries, where inadequate infection control practices and overuse of antibiotics exacerbate AMR. This underscores the need for targeted interventions that address both the microbiological and systemic factors contributing to SSIs. By understanding the scope and impact of SSIs, healthcare professionals can better appreciate the urgency of addressing AMR in surgical settings.

Table 1 Classification and Clinical Impact of Surgical Site Infections (SSIs)

SSI Type	Description	Common Pathogens	Incidence Rate	Clinical Impact	Economic Impact (US Estimates)	References
Superficial Incisional	Infection involving skin and subcutaneous tissue at the incision site; presents with localized pain, redness, swelling, and purulent discharge.	Staphylococcus aureus (including MRSA), Streptococcus spp.	1-3% of all surgeries	Delayed wound healing, mild systemic symptoms; low mortality risk but high reoperation rate (up to 20%).	Additional hospital stay: 3-5 days; Cost: $2,000-$5,000 per case.	Anderson et al. [1], Badia et al. [2]
Deep Incisional	Infection extending into fascial and muscle layers; often associated with fever, deep pain, and abscess formation.	S. aureus (MRSA), Enterococcus spp., Gram-negative rods (e.g., E. coli).	0.5-2% of surgeries	Increased risk of sepsis (10-20%), prolonged recovery (2-4 weeks), higher reoperation rate (30-50%).	Additional stay: 7-10 days; Cost: $10,000-$20,000 per case; Annual US burden: $1-2 billion.	Zimlichman et al. [3], Engemann et al. [9]
Organ/Space	Infection in any part of the	Gram-negative bacteria (e.g., E.	0.5-1% of surgeries	High sepsis risk (30-	Additional stay: 10-20	Allegranzi et al. [4],

	anatomy other than the incision (e.g., intra-abdominal abscess post-appendectomy); severe systemic involvement.	coli, P. aeruginosa), anaerobes (e.g., Bacteroides).	(higher in abdominal procedures: up to 5%).	50%), organ failure, mortality rate: 10-25%; extended ICU stays.	days; Cost: $20,000-$50,000 per case; Contributes to 30% of SSI-related deaths.	Magill et al. [33]
Implant-Related	Infections associated with prosthetic devices (e.g., joint replacements); biofilms common; occurs up to 90 days post-op.	MRSA, Coagulase-negative staphylococci, P. aeruginosa.	1-5% in orthopedic implants; up to 10% in high-risk cases.	Chronic infection, implant failure (requiring removal in 40-60% cases), long-term disability.	Additional stay: 14-30 days; Cost: $50,000-$100,000 per case (including revision surgery); Annual US burden: $500 million-$1 billion.	Høiby et al. [19], Owens & Stoessel [39]
Overall SSIs	All types combined; typically within 30 days post-op (90 days for implants).	Mixed flora: 50% Gram-positive, 40% Gram-negative, 10% anaerobes/fungi.	2-5% globally; higher in LMICs (5-20%).	Morbidity: 20-30% of healthcare-associated infections; Mortality: 3-5% overall, up to 20% in resistant cases.	Global annual cost: $10-20 billion; Extended stays: 7-11 days average; Lost productivity: $5-10 billion.	Badia et al. [2], Zimlichman et al. [3], Cassini et al. [16]

1.2. The Growing Global Challenge of Antimicrobial Resistance in Surgical Settings

Antimicrobial resistance is a global public health crisis that undermines the effectiveness of antibiotics, particularly in surgical care. The World Health Organization (WHO) has identified AMR as one of the top ten global health threats, with resistant infections causing over 1.2 million deaths annually [5]. In surgical settings, AMR complicates the prevention and treatment of SSIs, as standard prophylactic antibiotics like cefazolin or vancomycin lose efficacy against resistant strains. A seminal study by Laxminarayan et al. [6] highlights that AMR in SSIs is driven by the selective pressure from widespread antibiotic use, coupled with inadequate infection control measures in healthcare facilities.

The epidemiology of AMR in SSIs varies by region and healthcare setting. In high-income countries, MRSA remains a dominant resistant pathogen, with prevalence rates in SSIs ranging from 20–50% in some hospitals [7]. In contrast, low- and middle-income countries face a higher burden of multidrug-resistant Gram-negative bacteria, such as extended-spectrum beta-lactamase (ESBL)-producing *E. coli* and *Klebsiella pneumoniae*. A study by Saleem et al. [8] found that in Pakistan, over 60% of SSI pathogens exhibited multidrug resistance, largely due to inappropriate antibiotic prescribing practices. These regional disparities highlight the need for tailored strategies to address AMR based on local resistance patterns and healthcare infrastructure.

The consequences of AMR in surgical settings are far-reaching, affecting both patient outcomes and healthcare systems. Resistant SSIs are associated with higher rates of reoperation, intensive care unit admissions, and mortality. For example, Engemann et al. [9] reported that patients with MRSA-related SSIs had a threefold higher risk of death compared to those with methicillin-susceptible infections. Furthermore, the economic burden of AMR is substantial, with resistant infections increasing treatment costs by up to 40% compared to susceptible infections [10]. Addressing this challenge requires a multifaceted approach, including improved antibiotic stewardship, enhanced infection control, and the development of novel therapeutics.

The rapid spread of AMR in surgical settings is also linked to global factors such as antibiotic misuse in agriculture and community settings. According to O'Neill [11], inappropriate antibiotic use outside hospitals contributes significantly to the resistance pool, with resistant bacteria spreading to surgical patients through environmental and community transmission. This interconnectedness underscores the need for global cooperation to mitigate AMR, as resistant pathogens do not respect geographic boundaries. Efforts to combat AMR in SSIs must therefore integrate local and global strategies to achieve sustainable outcomes.

1.3. Importance of Integrating Medical, Surgical, and Pharmaceutical Perspectives

The complexity of AMR in SSIs necessitates an interdisciplinary approach that bridges medicine, surgery, and pharmacy. Surgeons play a critical role in preventing SSIs through meticulous surgical techniques and adherence to infection control protocols. However, as Berrios-Torres et al. [12] emphasize, the effectiveness of surgical prophylaxis relies heavily on appropriate antibiotic selection and timing, which requires collaboration with pharmacists. Pharmacists contribute expertise in antimicrobial stewardship, ensuring that antibiotics are used judiciously to minimize resistance development. This synergy is essential for optimizing patient outcomes and reducing the burden of AMR.

Medical professionals, including infectious disease specialists, provide critical insights into the diagnosis and management of resistant SSIs. A study by Manoukian et al. [13] demonstrated that involving infectious disease consultants in SSI management reduced inappropriate antibiotic use by 30%, highlighting the value of medical expertise. Rapid diagnostic tools, such as polymerase chain reaction (PCR) for pathogen identification, further enhance the ability to tailor treatments to specific resistance profiles. By integrating medical diagnostics with surgical and pharmaceutical interventions, healthcare teams can develop more effective strategies to combat AMR.

Pharmacy plays a pivotal role in developing and implementing innovative therapeutic approaches. For instance, research by Boucher et al. [14] highlights the potential of novel antibiotics and combination therapies to overcome resistance in SSIs. Pharmacists also contribute to patient education and policy development, ensuring that antibiotic use is aligned with evidence-based guidelines. In a classic study by Dellit et al. [15], pharmacist-led stewardship programs reduced hospital-wide antibiotic consumption by 20%, demonstrating their impact on AMR mitigation. Collaboration between pharmacists, surgeons, and medical professionals is thus critical for addressing the multifaceted challenges of AMR in SSIs.

The integration of these disciplines also extends to policy and education. Global initiatives, such as the WHO's Global Action Plan on AMR, emphasize the need for interdisciplinary training to equip healthcare professionals with the skills to combat resistance [5]. By fostering collaboration, healthcare systems can develop comprehensive strategies that address the biological, clinical, and systemic factors driving AMR in SSIs. This review will explore these interdisciplinary approaches, highlighting innovative solutions and future directions for mitigating the threat of AMR in surgical settings.

1.4. Objectives and Scope of the Review Paper

This review aims to provide a comprehensive analysis of AMR in SSIs, focusing on its underlying mechanisms, epidemiological trends, and innovative mitigation strategies. By synthesizing current literature, the paper will elucidate the biological and pharmacological factors contributing to resistance, the global burden of resistant SSIs, and the challenges in their management. According to Cassini et al. [16], AMR-related infections, including SSIs, account for significant preventable mortality in Europe, underscoring the need for targeted interventions. The review will also explore interdisciplinary approaches that integrate medicine, surgery, and pharmacy to address this crisis.

The scope of the paper encompasses recent advancements in antimicrobial prophylaxis, non-antibiotic therapies, and infection prevention strategies. It will highlight emerging technologies, such as nanotechnology and bacteriophage therapy, as potential solutions to combat resistant pathogens. Findings from Ventola [17] suggest that such innovations could revolutionize SSI management, offering alternatives to traditional antibiotics. The review will also address the role of policy and education in fostering sustainable change, drawing on global and regional perspectives to provide a holistic understanding of the issue.

By focusing on verifiable data from peer-reviewed sources, this paper ensures a rigorous and evidence-based approach. The review will avoid speculative claims, grounding its arguments in studies available on Google Scholar, such as those by Anderson et al. [1] and Laxminarayan et al. [6]. The ultimate goal is to provide actionable insights for healthcare professionals and policymakers, emphasizing interdisciplinary collaboration as a cornerstone for mitigating AMR in SSIs. The subsequent sections will delve into the mechanisms, epidemiology, and innovative strategies to address this pressing challenge.

2. Mechanisms of Antimicrobial Resistance in SSIs

Understanding the mechanisms of antimicrobial resistance (AMR) in surgical site infections (SSIs) is critical for developing effective prevention and treatment strategies. AMR in SSIs arises from complex interactions between microbial genetics, environmental pressures, and pharmacological factors, rendering standard antibiotics less effective. This section explores the biological mechanisms driving resistance, the primary pathogens involved, and the pharmacological practices contributing to AMR in surgical settings, providing a foundation for addressing this growing challenge.

2.1. Biological Mechanisms of Resistance

Antimicrobial resistance in SSIs is driven by diverse biological mechanisms that enable pathogens to evade antibiotic action. According to Hrynyshyn et al. [18], resistance primarily arises through genetic mutations and horizontal gene transfer, which allow bacteria to acquire or develop resistance genes. Horizontal gene transfer, mediated by plasmids, transposons, or integrons, facilitates the rapid spread of resistance across bacterial populations, particularly in hospital settings where selective pressure from antibiotics is high. For instance, the dissemination of beta-lactamase genes among Gram-negative bacteria has significantly reduced the efficacy of penicillins and cephalosporins in SSI treatment. These genetic adaptations are compounded by the hospital environment, where resistant strains can persist on surfaces and medical equipment, increasing the risk of SSIs.

Biofilm formation is another critical mechanism contributing to AMR in SSIs. Findings from Høiby et al. [19] indicate that biofilms—complex communities of bacteria encased in a protective extracellular matrix—are prevalent in implant-related SSIs, such as those involving prosthetic joints or catheters. Biofilms shield bacteria from antibiotics and host immune responses, reducing drug penetration and efficacy. A seminal study by Stewart and Costerton [20] demonstrated that biofilm-associated bacteria can be up to 1,000 times more resistant to antibiotics than their planktonic counterparts. This resistance is particularly problematic in surgical settings, where biofilms can form on surgical implants, leading to chronic infections that are difficult to eradicate. Biofilms consist of a complex structure that enhances bacterial survival; Figure 1 illustrates the major components of a biofilm, including water, microbial cells, and extracellular polymeric substances, providing insight into why they confer up to 1,000-fold increased resistance to antibiotics.

Efflux pumps and enzymatic degradation further enhance bacterial resistance. Efflux pumps actively expel antibiotics from bacterial cells, reducing intracellular drug concentrations. According to Gaurav et al. [21], efflux systems, such as those in *Pseudomonas aeruginosa*, confer resistance to multiple antibiotic classes, including fluoroquinolones and aminoglycosides, commonly used in SSI prophylaxis. Additionally, enzymes like extended-spectrum beta-lactamases (ESBLs) and carbapenemases degrade antibiotics before they can act. A study by Bush and Jacoby [22] highlighted the increasing prevalence of ESBL-producing *Enterobacteriaceae* in SSIs, which compromises the use of third-generation cephalosporins. These mechanisms collectively contribute to the persistence of resistant pathogens in surgical wounds. Bacterial resistance involves multiple interconnected strategies; Figure 2 schematically represents key antibiotic resistance mechanisms, including increased efflux, target modification, and enzymatic degradation, which collectively challenge SSI treatment.

The interplay of these mechanisms creates a formidable challenge for SSI management. For example, multidrug-resistant (MDR) pathogens combine multiple resistance strategies, such as biofilm formation and efflux pumps, to evade treatment. Research by Davies and Davies [23] emphasizes that the cumulative effect of these mechanisms accelerates the spread of resistance, particularly in high-risk surgical populations. Addressing these biological drivers requires a deeper understanding of microbial genetics and behavior, informing the development of targeted therapies to overcome resistance in SSIs. For a comprehensive visualization of the diverse biological mechanisms underpinning AMR in SSIs, Table 2 details each mechanism, involved pathogens, resistance conferral, treatment impacts, examples, counter-strategies, and key references.



Figure 1 Key Constituents of a Biofilm and Their Relative Proportions. Reproduced from Hrynyshyn et al. [18] with permission, under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).



Figure 2 Schematic representation of antibiotic resistance mechanisms. Six different resistance mechanisms are found in bacteria. (a) Increased efflux by efflux systems; (b) reduced uptake due to change in membrane permeability; (c) enzymatic degradation; (d) target site protection; (e) target site modification and (f) expression of alternative enzymes or off-target sites. Reproduced from Gaurav et al. [21] with permission

Table 2 Biological Mechanisms of Antimicrobial Resistance in SSIs

Mechanism	Description	Pathogens Commonly Involved	How It Confers Resistance	Impact on SSI Treatment	Examples/Genetic Elements	Strategies to Overcome	References
Genetic Mutations	Spontaneous changes in bacterial DNA leading to altered drug targets (e.g., modified penicillin-binding proteins).	S. aureus (MRSA), E. coli.	Reduces antibiotic binding affinity; e.g., mutations in gyrA gene for fluoroquinolone resistance.	Increases treatment failure by 20-30%; requires higher doses or alternatives.	mecA gene in MRSA; point mutations in rpoB for rifampin.	Targeted inhibitors (e.g., beta-lactamase inhibitors).	Hrynyshyn et al. [18], Davies & Davies [23]
Horizontal Gene Transfer	Transfer of resistance genes via plasmids, transposons, or integrons between bacteria.	Gram-negative bacteria (e.g., K. pneumoniae, P. aeruginosa).	Rapid dissemination in hospital environments; e.g., plasmid-mediated beta-lactamase spread.	Accelerates MDR outbreaks in SSIs; 40-60% of resistant cases in LMICs.	blaCTX-M genes for ESBL; carbapenemase plasmids (e.g., KPC).	Infection control to limit transmission.	Hrynyshyn et al. [18], Bush & Jacoby [22]
Biofilm Formation	Bacteria aggregate in protective extracellular matrix on surfaces/implants.	P. aeruginosa, S. aureus, A. baumannii.	Shields from antibiotics and immune system; reduces drug penetration by up to 1,000-fold.	Chronic SSIs in 50-70% of implant cases; hard to eradicate without removal.	Polysaccharide matrix; quorum-sensing regulated.	Biofilm disruptors (e.g., quorum-sensing inhibitors).	Høiby et al. [19], Stewart & Costerton [20]
Efflux Pumps	Membrane proteins that actively pump out antibiotics from the cell.	P. aeruginosa, A. baumannii, Enterobacteriaceae.	Lowers intracellular drug concentration; confers multi-class resistance (e.g., to tetracyclines, fluoroquinolones).	Reduces efficacy in 30-50% of Gram-negative SSIs; promotes MDR.	MexAB-OprM system in P. aeruginosa; AcrAB-TolC in E. coli.	Efflux pump inhibitors (e.g., phenylalanine-arginine beta-naphthylamide).	Gaurav et al. [21], Piddock [76]
Enzymatic Degradation	Production of enzymes that hydrolyze or modify antibiotics.	Enterobacteriaceae (ESBL producers), CRE.	Inactivates drugs like beta-lactams; e.g., carbapenemases break	High mortality (20-30%) in CRE SSIs; limits	NDM-1, OXA-48 carbapenemases; TEM/SHV beta-lactamases.	Combination therapies (e.g., avibactam with	Bush & Jacoby [22], Drawz & Bonomo [74]

			down last-resort antibiotics.	options to toxic alternatives.		ceftazidime).	
Reduced Permeability	Alterations in outer membrane porins reducing antibiotic entry.	Gram-negative bacteria (e.g., P. aeruginosa, E. coli).	Limits drug access to intracellular targets; synergizes with other mechanisms.	Contributes to 40% of MDR in abdominal SSIs.	OprD porin mutations in P. aeruginosa.	Nanoparticle delivery to bypass membranes.	Gaurav et al. [21], Peleg & Hooper [28]

2.2. Common Pathogens in SSIs

Table 3 Common Pathogens in SSIs and Their Resistance Profiles

Pathogen	SSI Types Commonly Associated	Prevalence in SSIs (%)	Key Resistance Mechanisms	Resistant Strains	Treatment Challenges	Global Variations	References
Staphylococcus aureus	incisional, implant-related.	globally; 40-50% in orthopedics.	Beta-lactam resistance via mecA gene; biofilms.	MRSA (20-50% in HICs), VRSA (rare).	Vancomycin toxicity; reduced efficacy in biofilms.	Higher MRSA in HICs; MDR in LMICs.	Klevens et al. [24], Hidron et al. [7]
Escherichia coli	Organ/space, abdominal SSIs.	10-20%; higher in LMICs (30-40%).	ESBL production; carbapenemases.	ESBL-E. coli (40-60%), CRE (5-10%).	Limited to colistin (nephrotoxic); high mortality (20%).	Prevalent MDR in Asia/Africa.	Sievert et al. [25], Saleem et al. [8]
Pseudomonas aeruginosa	Deep/organ/space, burn/trauma SSIs.	5-15%; up to 25% in ICUs.	Efflux pumps, reduced permeability, biofilms.	MDR P. aeruginosa (30-50%).	Resistance to carbapenems/aminoglycosides; biofilm persistence.	Common in LMICs with poor IPC.	Peleg & Hooper [28]
Klebsiella pneumoniae	Abdominal, urological SSIs.	5-10%; 20-30% in LMICs.	ESBL, carbapenemases (KPC/NDM).	ESBL-K. pneumoniae (50%), CRE (10-20%).	Combination therapy needed; 30% treatment failure.	High CRE in South Asia/Europe.	Tumbarello et al. [36], Bush & Jacoby [22]
Enterococcus spp.	Abdominal, cardiac SSIs.	5-10%; higher in transplants (15-20%).	Vancomycin resistance via van genes.	VRE (20-30% in HICs).	Linezolid/daptomycin alternatives; gut colonization risk.	Rising in oncology/transplant settings.	Arias & Murray [27]
Acinetobacter baumannii	Trauma, ICU-related SSIs.	2-5%; up to 10% in war zones/LMICs.	Multi-efflux, carbapenemases, biofilms.	MDR A. baumannii (70-80%).	Colistin as last resort; high resistance to all classes.	Prevalent in Middle East/Asia.	Peleg & Hooper [28], Naylor et al. [26]

Anaerobes (e.g., Bacteroides)	Organ/space abdominal SSIs.	5-10%.	Beta-lactamase production.	Metronidazole-resistant (rare, <5%).	Often polymicrobial; surgical drainage required.	Higher in GI surgeries in LMICs.	Owens & Stoessel [39]

The microbial profile of SSIs is dominated by a few key pathogens, with resistant strains posing significant therapeutic challenges. Methicillin-resistant *Staphylococcus aureus* (MRSA) is a leading cause of SSIs, particularly in orthopedic and cardiac surgeries. According to Klevens et al. [24], MRSA accounts for approximately 30–50% of *S. aureus*-related SSIs in the United States, driven by the acquisition of the *mecA* gene, which confers resistance to beta-lactam antibiotics. MRSA infections are associated with higher rates of treatment failure and prolonged hospital stays, necessitating the use of alternative agents like vancomycin, which have their own limitations, including toxicity and reduced efficacy against vancomycin-intermediate strains.

Multidrug-resistant Gram-negative bacteria, such as *Pseudomonas aeruginosa* and *Escherichia coli*, are increasingly implicated in SSIs, particularly in abdominal and urological procedures. A study by Sievert et al. [25] reported that ESBL-producing *E. coli* and *Klebsiella pneumoniae* are prevalent in SSIs in low-resource settings, where infection control measures are often inadequate. These pathogens exhibit resistance to multiple antibiotic classes, including cephalosporins, fluoroquinolones, and carbapenems, complicating treatment. The rise of carbapenem-resistant *Enterobacteriaceae* (CRE) is particularly concerning, as these organisms are associated with high mortality rates in SSI patients [26].

Other pathogens, such as *Enterococcus* species and *Acinetobacter baumannii*, also contribute to the AMR burden in SSIs. According to Arias and Murray [27], vancomycin-resistant *Enterococcus* (VRE) is a growing concern in surgical settings, particularly in transplant and oncology patients. Similarly, *A. baumannii*, known for its environmental resilience and multidrug resistance, is a significant cause of SSIs in intensive care units. Research by Peleg and Hooper [28] highlights that *A. baumannii*'s ability to form biofilms and resist multiple antibiotics makes it a formidable pathogen in surgical wound infections. The diversity of resistant pathogens underscores the need for tailored antimicrobial strategies based on local microbiological profiles. To encapsulate the microbial landscape of SSIs, Table 3 outlines common pathogens, their associations, prevalence, resistance profiles, challenges, and global variations.

The prevalence of these pathogens varies by surgical procedure and geographic region. For example, a study by Boucher et al. [14] noted that MRSA is more common in high-income countries, while MDR Gram-negative bacteria dominate in developing nations due to differences in antibiotic use and infection control practices. This variability complicates the standardization of SSI prevention protocols and highlights the importance of surveillance to track resistance patterns. Effective management of SSIs requires rapid identification of these pathogens and their resistance profiles to guide appropriate therapy.

2.3. Pharmacological Factors Contributing to Resistance

Pharmacological practices, particularly the misuse and overuse of antibiotics in perioperative care, are major drivers of AMR in SSIs. According to Bratzler et al. [29], inappropriate antibiotic prophylaxis—such as incorrect timing, prolonged duration, or use of broad-spectrum agents—contributes significantly to resistance development. For instance, administering antibiotics too early or continuing them beyond the recommended 24-hour postoperative period increases selective pressure, promoting the emergence of resistant strains. A study by Hawn et al. [30] found that prolonged prophylaxis was associated with a 1.5-fold increase in SSI rates due to resistant pathogens, highlighting the need for adherence to evidence-based guidelines.

Suboptimal dosing of antibiotics also exacerbates AMR. Findings from Roberts et al. [31] indicate that underdosing, often due to inadequate adjustment for patient factors like body weight or renal function, results in subtherapeutic drug concentrations, allowing resistant mutants to proliferate. Conversely, overuse of broad-spectrum antibiotics, such as third-generation cephalosporins, disrupts the patient's microbiome, increasing the risk of colonization by resistant pathogens. Research by Spellberg et al. [32] emphasizes that this disruption creates a reservoir for resistant bacteria, which can subsequently cause SSIs. Pharmacists play a critical role in optimizing dosing regimens to balance efficacy and resistance prevention.

Inappropriate antibiotic selection further compounds the problem. A classic study by Dellit et al. [15] demonstrated that the indiscriminate use of antibiotics, particularly in settings with limited diagnostic capabilities, drives the selection of MDR pathogens. In low-resource settings, where microbiological testing is often unavailable, clinicians may resort to empirical broad-spectrum therapy, accelerating resistance. According to Saleem et al. [8], this practice is particularly prevalent in developing countries, where up to 70% of antibiotic prescriptions for surgical prophylaxis are inappropriate. Implementing antibiotic stewardship programs is essential to curb these practices and reduce AMR in SSIs.

The interplay between pharmacological factors and microbial resistance highlights the need for interdisciplinary collaboration. Pharmacists, in collaboration with surgeons and infectious disease specialists, can ensure that antibiotic prophylaxis aligns with guidelines, such as those from the Centers for Disease Control and Prevention (CDC) [12]. By optimizing antibiotic use, healthcare teams can mitigate the selective pressure driving AMR, preserving the efficacy of existing antibiotics for SSI prevention and treatment.

3. Epidemiology of AMR in SSIs

The epidemiology of antimicrobial resistance (AMR) in surgical site infections (SSIs) reveals a complex and growing global challenge, with significant variations in prevalence, risk factors, and outcomes across regions and healthcare settings. Understanding the distribution and determinants of resistant SSIs is crucial for informing targeted interventions and optimizing resource allocation. This section examines the global prevalence of AMR in SSIs, the key risk factors driving their occurrence, and the clinical and economic burden imposed by resistant infections, highlighting the urgent need for interdisciplinary strategies to address this public health crisis.

3.1. Global Prevalence of AMR in SSIs

The global prevalence of AMR in SSIs varies widely, influenced by regional differences in healthcare infrastructure, antibiotic use, and infection control practices. According to Allegranzi et al. [4], SSIs are the most common healthcare-associated infections in low- and middle-income countries (LMICs), with resistant pathogens accounting for up to 60% of cases in some regions. In high-income countries, such as the United States and European nations, methicillin-resistant *Staphylococcus aureus* (MRSA) remains a dominant resistant pathogen, with prevalence rates in SSIs ranging from 20–50% [7]. A comprehensive study by Magill et al. [33] reported that in U.S. hospitals, approximately 30% of SSIs involve multidrug-resistant (MDR) pathogens, including MRSA and extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria. This high prevalence underscores the global scope of the AMR challenge in surgical settings.

In LMICs, the burden of AMR in SSIs is exacerbated by limited access to microbiological diagnostics and standardized infection control measures. A study by Farret et al. [34] in Brazil found that 40% of SSI pathogens were MDR, with ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* being particularly prevalent in abdominal surgeries. Similarly, research by Saleem et al. [8] in Pakistan highlighted that over 60% of SSI isolates exhibited resistance to multiple antibiotic classes, driven by widespread antibiotic misuse. These findings indicate that LMICs face a disproportionate burden of resistant SSIs, often linked to overcrowding in hospitals and inadequate sterilization practices.

Regional variations in AMR prevalence are also influenced by differences in surgical practices and patient populations. For example, a study by Rosenthal et al. [35] across 82 hospitals in Latin America, Africa, and Asia reported that SSIs following cesarean sections had a higher incidence of MDR pathogens compared to orthopedic procedures, reflecting procedure-specific risks. In contrast, high-income countries with robust surveillance systems, such as those in Europe, report lower overall SSI rates but a higher proportion of resistant infections due to advanced diagnostic capabilities [16]. These disparities highlight the need for global surveillance networks to track AMR trends and inform localized prevention strategies. Regional disparities in AMR are evident across the globe; Figure 3 maps the distribution of major multi-resistant strains, emphasizing the higher burden of MDR Gram-negative bacteria in LMICs as discussed.



Figure 3 Global distribution of the main multi-resistant strains and antimicrobial resistance (CD: Clostridium difficile; CRE: carbapenem-resistant Enterobacterales; ESBL: extended-spectrum beta-lactamase; MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus; TB: multidrug-resistant Mycobacterium tuberculosis). Reproduced from Oliveira et al. [36] with permission, under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

The increasing prevalence of carbapenem-resistant Enterobacteriaceae (CRE) and other MDR pathogens in SSIs is a growing concern. According to Oliveira et al. [36], CRE infections in SSIs are associated with a 20–30% mortality rate, particularly in immunocompromised patients. The global spread of these pathogens, facilitated by international travel and healthcare-associated transmission, underscores the interconnected nature of AMR. Efforts to address this issue must prioritize standardized surveillance and data sharing to map the epidemiology of resistant SSIs accurately.

3.2. Risk Factors for AMR in SSIs

The development of AMR in SSIs is influenced by a combination of patient-related, procedure-related, and systemic risk factors. Patient-specific factors, such as comorbidities and immune status, significantly increase the likelihood of resistant infections. According to Anaya and Dellinger [37], patients with diabetes, obesity, or immunosuppression (e.g., due to cancer or organ transplantation) are at higher risk of SSIs caused by MDR pathogens. These conditions impair wound healing and immune responses, creating an environment conducive to resistant bacterial colonization. For instance, a study by Martin et al. [38] found that diabetic patients undergoing surgery had a 2.5-fold higher risk of MRSA-related SSIs compared to non-diabetic patients, emphasizing the role of comorbidities in AMR.

Procedure-related factors also contribute significantly to the risk of resistant SSIs. Complex or prolonged surgeries, particularly those involving implants or invasive devices, increase exposure to resistant pathogens. Findings from Owens and Stoessel [39] indicate that surgeries lasting over three hours or involving prosthetic materials, such as hip replacements, are associated with a higher incidence of biofilm-forming MDR pathogens like *Pseudomonas aeruginosa*. Additionally, inadequate surgical site preparation or breaches in sterile technique can introduce resistant bacteria into wounds. A seminal study by Mangram et al. [40] highlighted that improper timing of antibiotic prophylaxis, such as administration more than one hour before incision, increases the risk of resistant SSIs by up to 50%.

Systemic factors, including healthcare practices and environmental conditions, further exacerbate the risk of AMR in SSIs. In LMICs, limited access to clean water, poor sanitation, and overcrowded hospital wards create ideal conditions for the spread of resistant pathogens. Research by Pittet et al. [41] demonstrated that hospitals with inadequate hand hygiene compliance had a 30% higher incidence of MDR SSIs compared to those with robust infection control protocols.

Furthermore, inappropriate antibiotic prescribing practices, such as the use of broad-spectrum agents for prophylaxis, drive resistance by exerting selective pressure on bacterial populations [8]. These systemic issues highlight the need for comprehensive infection control and stewardship programs to mitigate AMR risks.

Emerging evidence also points to the role of patient colonization with resistant bacteria prior to surgery. According to Huang et al. [42], preoperative nasal colonization with MRSA is a significant predictor of postoperative SSI, with colonized patients having a fourfold higher risk of infection. Screening and decolonization protocols, such as the use of mupirocin nasal ointment, have shown promise in reducing this risk, but their implementation remains inconsistent, particularly in resource-limited settings. Addressing these diverse risk factors requires a multifaceted approach that combines patient screening, optimized surgical techniques, and systemic improvements in healthcare delivery. To systematically categorize and quantify the multifaceted risk factors for AMR in SSIs, Table 4 details categories, specifics, risks, pathogens, prevention, evidence, and references.

Table 4 Risk Factors for AMR in SSIs Categorized by Type

Category	**Specific Risk Factors**	**Relative Risk Increase**	**Associated Pathogens**	**Prevention Strategies**	**Evidence from Studies**	**References**
Patient-Related	Diabetes, obesity, immunosuppression (e.g., cancer, transplants).	2-3 fold	MRSA, CRE.	Glycemic control; preoperative optimization.	Diabetic patients: 2.5x MRSA risk.	Martin et al. [38], Anaya & Dellinger [37]
Procedure-Related	Prolonged surgery (>3 hours), implants, invasive devices.	1.5-2 fold	P. aeruginosa, biofilms.	Minimize duration; antibiotic-impregnated implants.	30% higher in orthopedic implants.	Owens & Stoessel [39], Hawn et al. [30]
Systemic/Healthcare	Poor hand hygiene, overcrowding, inadequate sterilization.	1.5-3 fold	MDR Gram-negatives.	IPC protocols; training.	30% higher with low hygiene compliance.	Pittet et al. [41], Allegranzi et al. [4]
Preoperative Colonization	Nasal MRSA, gut MDR bacteria.	3-4 fold	MRSA, VRE.	Screening/decolonization (e.g., mupirocin).	4x risk if colonized.	Huang et al. [42], Harbarth et al. [60]
Antibiotic-Related	Inappropriate prophylaxis (timing, duration, spectrum).	1.5-2 fold	ESBL producers, CRE.	Adherence to guidelines; stewardship.	50% increase with improper timing.	Bratzler et al. [29], Mangram et al. [40]
Environmental	Hospital surfaces, community antibiotic misuse.	1.2-2 fold	A. baumannii, P. aeruginosa.	UV disinfection; policy on agriculture use.	Contributes to 20-30% resistance pool.	O'Neill [11], Dancer [71]

3.3. Economic and Clinical Burden

The economic and clinical burden of AMR in SSIs is substantial, affecting patients, healthcare systems, and society at large. Clinically, resistant SSIs are associated with increased morbidity and mortality due to treatment failures and delayed recovery. A study by Engemann et al. [9] reported that patients with MRSA-related SSIs had a threefold higher risk of mortality and a 1.5-fold increase in hospital readmissions compared to those with susceptible infections. These infections often require prolonged antibiotic therapy, additional surgical interventions, and extended hospital stays, which exacerbate patient suffering and complicate recovery. Understanding the pathways of AMR impact aids in quantifying its burden; Figure 4 offers a conceptual model depicting patient progression through surgical pathways, incorporating health states, treatment decisions, and AMR variables.

Economically, resistant SSIs impose a significant financial burden on healthcare systems. According to Zimlichman et al. [3], SSIs, particularly those caused by MDR pathogens, contribute to an additional \$3.5–\$10 billion annually in healthcare costs in the United States, driven by prolonged hospitalizations and the use of costly alternative antibiotics. In a comprehensive analysis by Roberts et al. [10], the cost of treating a single resistant SSI was estimated to be 40% higher than that of a susceptible infection, with expenses stemming from intensive care unit stays, diagnostic tests, and second-line therapies. In LMICs, where healthcare budgets are constrained, this burden can overwhelm systems, leading to reduced access to care for other patients.

The societal impact of AMR in SSIs extends beyond direct healthcare costs. Resistant infections contribute to lost productivity due to prolonged recovery periods and increased disability. A study by Smith and Coast [43] estimated that the societal cost of AMR, including SSIs, could reach \$100 trillion globally by 2050 if left unchecked, driven by reduced workforce participation and increased healthcare expenditures. Additionally, the psychological toll on patients, including anxiety and reduced quality of life, adds to the overall burden. Research by Badia et al. [2] highlighted that patients with resistant SSIs reported significantly lower quality-of-life scores compared to those with non-resistant infections, underscoring the need for effective interventions.

The global nature of the AMR crisis necessitates urgent action to mitigate its economic and clinical impact. According to Cassini et al. [16], resistant SSIs contribute to over 33,000 attributable deaths annually in Europe alone, with a significant proportion preventable through improved infection control and antibiotic stewardship. Addressing this burden requires investment in surveillance, rapid diagnostics, and novel therapies to reduce the incidence and impact of resistant SSIs. By quantifying the economic and clinical consequences, healthcare systems can prioritize resources and policies to combat AMR effectively.



Figure 4 A conceptual framework for assessing the effects of antimicrobial resistance on patients undergoing surgery. The diagram illustrates patient trajectories along a surgical care pathway susceptible to infections, flowing from left to right. At the outset (far left), patients enter one of three initial health states (blue circles) and advance via treatment choices (rectangles). Health states are denoted by circles, while rectangles signify decision points in the pathway; (c) indicates a condensed branch that parallels another at the same stage (e.g., the "No Prophylaxis" route replicates the transitions and states of the "Prophylaxis" route). Yi denotes microbial species (where i = 1 to m, encompassing clinically significant microbes); Xp,t signifies prophylactic antibiotics (p = 1 to n) administered at time t; Tx,t represents

therapeutic antibiotics for SSI management (t = 1 to q), with possible overlap (p = t). The duration patients remain in each state (shown by a curved looping arrow) varies. Reproduced from Naylor et al. [26] with permission, under the terms of the Creative Commons Attribution License (CC BY)

4. Current Challenges in Managing AMR in SSIs

Managing antimicrobial resistance (AMR) in surgical site infections (SSIs) presents multifaceted challenges that span diagnostic, therapeutic, and systemic domains. The increasing prevalence of multidrug-resistant (MDR) pathogens, coupled with limitations in current medical practices and healthcare infrastructure, complicates efforts to prevent and treat resistant SSIs effectively. This section examines the diagnostic limitations hindering timely identification of resistant pathogens, the therapeutic challenges posed by reduced antibiotic efficacy, and the systemic barriers, such as inconsistent antibiotic stewardship and variable guidelines, that impede progress in combating AMR in surgical settings.

4.1. Diagnostic Limitations

Timely and accurate diagnosis of resistant pathogens in SSIs is critical for effective treatment, yet significant diagnostic limitations persist. According to Didelot et al. [44], conventional microbiological culture methods, which remain the gold standard for identifying SSI pathogens, often require 48–72 hours to yield results, delaying targeted therapy. This delay is particularly problematic in the context of MDR pathogens, where inappropriate initial antibiotic therapy can lead to worse clinical outcomes. For instance, a study by Kollef et al. [45] found that delayed identification of resistant pathogens in SSIs increased the risk of treatment failure by 30%, underscoring the need for faster diagnostic tools.

The sensitivity and specificity of current diagnostic methods also pose challenges. Traditional culture-based techniques may fail to detect low bacterial loads or biofilm-associated infections, which are common in implant-related SSIs. Research by Costerton et al. [46] highlights that biofilms, which shield bacteria from detection, contribute to false-negative results in up to 40% of chronic SSI cases. Molecular techniques, such as polymerase chain reaction (PCR), offer improved sensitivity but are not widely available, particularly in low- and middle-income countries (LMICs). According to Tadesse et al. [47], limited access to advanced diagnostics in LMICs results in reliance on empirical antibiotic therapy, which exacerbates AMR by promoting the selection of resistant strains.

Cost and infrastructure barriers further limit diagnostic capabilities. Advanced diagnostic tools, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), enable rapid pathogen identification but require significant investment in equipment and trained personnel. A study by van Belkum et al. [48] noted that only 20% of hospitals in resource-limited settings have access to such technologies, leading to delayed or inaccurate diagnoses. This gap in diagnostic capacity contributes to the overuse of broad-spectrum antibiotics, driving resistance. Addressing these limitations requires investment in accessible, rapid, and cost-effective diagnostic platforms tailored to diverse healthcare settings.

Emerging diagnostic technologies, such as next-generation sequencing (NGS), hold promise for overcoming these challenges but face implementation hurdles. According to Goldberg et al. [49], NGS can identify resistance genes directly from clinical samples, offering insights into pathogen susceptibility within hours. However, its high cost and complexity limit its use in routine clinical practice. Bridging the diagnostic gap will require interdisciplinary collaboration to develop and deploy affordable, point-of-care diagnostics that can guide precise antibiotic therapy in SSI management.

4.2. Therapeutic Challenges

The therapeutic management of AMR in SSIs is hindered by the reduced efficacy of standard antibiotic regimens and the limitations of alternative treatments. According to Boucher et al. [14], the rise of MDR pathogens, such as MRSA and carbapenem-resistant Enterobacteriaceae (CRE), has diminished the effectiveness of first-line antibiotics like cefazolin and carbapenems, commonly used in surgical prophylaxis and treatment. A study by Cosgrove et al. [50] found that patients with MDR SSIs required longer courses of therapy and had a 25% higher rate of treatment failure compared to those with susceptible infections, highlighting the therapeutic challenge posed by resistance.

Alternative antibiotics, such as vancomycin, daptomycin, or colistin, are often employed to treat resistant SSIs, but these agents come with significant drawbacks. Findings from Falagas et al. [51] indicate that vancomycin, while effective against MRSA, has reduced penetration into tissues and biofilms, limiting its efficacy in deep or implant-related SSIs. Additionally, colistin, used for CRE infections, is associated with nephrotoxicity and neurotoxicity, complicating its use in vulnerable surgical patients. A seminal study by Paul et al. [52] reported that 20% of patients receiving colistin for resistant SSIs experienced adverse effects, underscoring the need for safer alternatives.

The scarcity of new antibiotics in the development pipeline exacerbates therapeutic challenges. According to Theuretzbacher et al. [53], the global antibiotic pipeline has dwindled, with only a few new agents targeting MDR Gram-negative pathogens, which are increasingly common in SSIs. This scarcity forces clinicians to rely on older, less effective drugs or combination therapies, which may not adequately address resistance. Research by Bassetti et al. [54] suggests that combination therapies, such as beta-lactamase inhibitor combinations, show promise but require further clinical validation for SSI treatment. The lack of robust therapeutic options underscores the urgency of developing novel antibiotics and alternative strategies.

The complexity of treating biofilm-associated SSIs further complicates therapy. Biofilms, which are prevalent in implant-related infections, reduce antibiotic penetration and increase resistance. According to Høiby et al. [19], biofilm-forming pathogens like *Pseudomonas aeruginosa* require higher antibiotic doses, which increase the risk of toxicity and resistance development. Non-antibiotic approaches, such as quorum-sensing inhibitors, are under investigation but remain experimental. Overcoming these therapeutic challenges requires innovative drug development and optimized treatment protocols tailored to resistant SSIs.

4.3. Systemic Issues

Systemic issues, including inconsistent antibiotic stewardship programs and variability in surgical prophylaxis guidelines, significantly hinder efforts to manage AMR in SSIs. Antibiotic stewardship programs, designed to optimize antibiotic use, are not uniformly implemented across healthcare settings. According to Dellit et al. [15], while stewardship programs have reduced inappropriate antibiotic prescribing by up to 20% in some hospitals, their adoption remains limited in LMICs due to resource constraints and lack of trained personnel. This inconsistency contributes to the overuse of broad-spectrum antibiotics, driving resistance in surgical settings.

Variability in surgical prophylaxis guidelines further complicates AMR management. Different organizations, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), provide slightly different recommendations on antibiotic choice, timing, and duration, leading to confusion among clinicians. A study by Bratzler et al. [29] found that non-adherence to CDC guidelines, such as prolonged prophylaxis beyond 24 hours, was associated with a 30% increase in resistant SSIs. In LMICs, where guidelines are often adapted to local contexts without rigorous validation, inappropriate prophylaxis practices are more common [8]. Standardizing and enforcing evidence-based guidelines is critical to reducing AMR.

Healthcare system factors, such as inadequate infection control and limited surveillance, exacerbate systemic challenges. Research by Pittet et al. [41] demonstrated that poor hand hygiene compliance and inadequate sterilization of surgical equipment contribute to the spread of MDR pathogens in hospitals. Additionally, limited surveillance systems in many regions hinder the tracking of resistance patterns, making it difficult to implement targeted interventions. According to Laxminarayan et al. [6], robust surveillance is essential for identifying emerging resistance trends and guiding antibiotic stewardship efforts.

Addressing these systemic issues requires global and local policy interventions. The WHO's Global Action Plan on AMR emphasizes the need for coordinated stewardship, surveillance, and infection control programs [5]. However, implementation remains uneven, particularly in resource-limited settings. Research by Mendelson et al. [55] suggests that capacity-building initiatives, such as training healthcare workers and investing in surveillance infrastructure, are essential for overcoming systemic barriers. By addressing these challenges, healthcare systems can create an enabling environment for effective AMR management in SSIs.

5. Innovative Mitigation Strategies

The escalating threat of antimicrobial resistance (AMR) in surgical site infections (SSIs) necessitates innovative strategies that go beyond traditional antibiotic therapy to address the complex interplay of biological, clinical, and systemic factors. Advances in antimicrobial prophylaxis, non-antibiotic approaches, infection prevention techniques, and pharmacological innovations offer promising solutions to mitigate AMR in surgical settings [56-59]. This section explores tailored prophylaxis regimens, novel non-antibiotic therapies, enhanced infection control measures, and the development of new pharmacological agents, highlighting their potential to reduce the burden of resistant SSIs through interdisciplinary collaboration.

5.1. Advances in Antimicrobial Prophylaxis

Optimizing antimicrobial prophylaxis is a cornerstone of SSI prevention, and recent advances focus on tailoring regimens to individual patient and procedure-specific risk profiles. According to Berrios-Torres et al. [12], personalized prophylaxis, based on factors such as patient comorbidities, surgical site, and local resistance patterns, can reduce the incidence of resistant SSIs by up to 20%. For instance, preoperative screening for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization allows for targeted use of vancomycin or daptomycin in high-risk patients, minimizing unnecessary broad-spectrum antibiotic exposure. A study by Harbarth et al. [60] demonstrated that MRSA decolonization with mupirocin nasal ointment and chlorhexidine bathing reduced SSI rates by 50% in colonized patients, highlighting the efficacy of risk-based prophylaxis.

Novel antibiotic delivery systems are revolutionizing prophylaxis by enhancing drug delivery to surgical sites. Local antibiotic carriers, such as antibiotic-impregnated cement or beads, deliver high concentrations of antibiotics directly to the surgical site, reducing systemic exposure and resistance development. Research by Anagnostakos [61] found that local delivery systems, such as gentamicin-loaded bone cement in orthopedic surgeries, decreased SSI rates by 30% compared to systemic prophylaxis alone. These systems are particularly effective in implant-related surgeries, where biofilms pose a significant challenge. However, their use is limited by cost and the need for specialized surgical expertise, particularly in low-resource settings.

Pharmacokinetic and pharmacodynamic (PK/PD) optimization further enhances prophylaxis efficacy. According to Roberts et al. [31], adjusting antibiotic doses based on patient-specific factors, such as body weight and renal function, ensures therapeutic concentrations at the surgical site, reducing the risk of resistance. For example, extended or continuous infusion of beta-lactam antibiotics, such as cefazolin, has been shown to improve tissue penetration and efficacy in high-risk procedures. A study by Adembri et al. [62] reported that optimized dosing regimens reduced the incidence of resistant SSIs by 25% in cardiac surgery patients. These advances underscore the importance of integrating pharmacological expertise into surgical care to combat AMR.

Despite these advancements, challenges remain in implementing tailored prophylaxis globally. In low- and middle-income countries (LMICs), limited access to screening tools and local delivery systems hinders adoption. Research by Tadesse et al. [47] suggests that resource constraints and lack of standardized protocols contribute to suboptimal prophylaxis practices, driving resistance. Overcoming these barriers requires investment in affordable diagnostic tools and training programs to ensure equitable access to advanced prophylaxis strategies.

5.2. Non-Antibiotic Approaches

Non-antibiotic approaches offer innovative alternatives to combat AMR in SSIs, particularly in the context of a dwindling antibiotic pipeline. Antimicrobial peptides (AMPs) are naturally occurring molecules that disrupt bacterial cell membranes, offering broad-spectrum activity against MDR pathogens. According to Hancock and Sahl [63], AMPs, such as defensins and cathelicidins, show promise in preventing SSIs by targeting resistant bacteria like MRSA and *Pseudomonas aeruginosa* without promoting resistance. A study by Zasloff [64] demonstrated that synthetic AMPs reduced bacterial loads in experimental wound models by 90%, suggesting their potential as topical agents in surgical settings. However, their clinical application is limited by high production costs and stability issues in vivo.

Bacteriophage therapy, which uses viruses to target specific bacteria, is another promising non-antibiotic approach. Research by Kutateladze and Adamia [65] highlights that phages can effectively target MDR pathogens in SSIs, particularly in biofilm-associated infections. A clinical trial by Wright et al. [66] showed that phage therapy reduced *P. aeruginosa* infections in chronic wounds by 70%, offering a potential model for SSI treatment. Phage therapy's specificity minimizes disruption to the host microbiome, a key advantage over broad-spectrum antibiotics. However, regulatory hurdles and the need for personalized phage cocktails limit its widespread adoption, particularly in resource-constrained settings.

Nanotechnology-based solutions are emerging as a novel strategy to combat resistant SSIs. Nanoparticles, such as silver or zinc oxide, exhibit antimicrobial properties by disrupting bacterial cell walls and inhibiting biofilm formation. According to Rai et al. [67], silver nanoparticles reduced MRSA colonization in surgical wounds by 80% in preclinical studies, offering a potential adjunct to traditional prophylaxis. Additionally, nanoparticle-based drug delivery systems enhance the efficacy of existing antibiotics by improving tissue penetration and targeting biofilms. Despite their promise, concerns about toxicity and long-term safety necessitate further research before clinical implementation.

The integration of these non-antibiotic approaches requires interdisciplinary collaboration between microbiologists, pharmacists, and surgeons. According to Ventola [17], combining AMPs or phages with existing therapies could enhance efficacy while reducing reliance on antibiotics. However, challenges such as scalability, cost, and regulatory approval must be addressed to translate these innovations into clinical practice. Continued investment in research and clinical trials is essential to validate these approaches for SSI management.

5.3. Infection Prevention and Control

Enhanced infection prevention and control (IPC) measures are critical for reducing the incidence of resistant SSIs. Advanced surgical site preparation techniques, such as the use of chlorhexidine-alcohol skin antiseptics, have been shown to reduce SSI rates significantly. A seminal study by Darouiche et al. [68] found that chlorhexidine-alcohol reduced SSI rates by 40% compared to povidone-iodine in clean-contaminated surgeries. Additionally, strict adherence to sterile techniques, such as double-gloving and minimizing operating room traffic, further reduces pathogen transmission. Research by Pittet et al. [41] emphasizes that improving hand hygiene compliance among surgical teams can decrease MDR SSI rates by up to 30%.

Advanced wound dressings and biomaterials offer innovative solutions for SSI prevention. Antimicrobial-impregnated dressings, such as those containing silver or iodine, create a barrier against resistant pathogens. According to Uçkay et al. [69], silver-impregnated dressings reduced SSI rates by 25% in orthopedic surgeries, particularly in high-risk patients. Similarly, bioresorbable materials, such as collagen-based matrices, promote wound healing while delivering antimicrobial agents directly to the surgical site. A study by Barnea et al. [70] demonstrated that collagen-based dressings reduced bacterial colonization in SSIs by 60%, highlighting their potential in infection control.

Environmental controls, such as high-efficiency particulate air (HEPA) filtration and ultraviolet (UV) disinfection, are increasingly used to reduce intraoperative contamination. According to Dancer [71], HEPA filtration in operating rooms decreased airborne bacterial loads by 50%, reducing the risk of resistant SSIs. However, these technologies are costly and often inaccessible in LMICs, where basic IPC measures like hand hygiene remain underutilized. Research by Allegranzi et al. [4] suggests that implementing low-cost IPC interventions, such as WHO-recommended hand hygiene protocols, could reduce SSI rates by 20% in resource-limited settings.

The success of IPC measures depends on consistent implementation and training. According to Leaper et al. [72], multidisciplinary training programs that educate surgical teams on evidence-based IPC practices can improve compliance and reduce resistant SSIs. However, cultural and logistical barriers, particularly in LMICs, hinder widespread adoption. Strengthening IPC infrastructure through global health initiatives and local capacity-building is essential to mitigate AMR in SSIs effectively.

5.4. Pharmacological Innovations

The development of new antibiotics and combination therapies is critical to overcoming AMR in SSIs. According to Boucher et al. [14], novel antibiotics, such as ceftazidime-avibactam and meropenem-vaborbactam, target MDR Gram-negative pathogens, including CRE, offering new options for SSI treatment. A study by Zhanel et al. [73] reported that ceftazidime-avibactam achieved a 90% clinical cure rate in infections caused by ESBL-producing bacteria, demonstrating its potential for resistant SSIs. However, the high cost and limited availability of these agents restrict their use, particularly in LMICs.

Combination therapies, which pair antibiotics with beta-lactamase inhibitors or adjuvants, enhance efficacy against resistant pathogens. Research by Drawz and Bonomo [74] highlights that combinations like piperacillin-tazobactam can overcome resistance in ESBL-producing *Enterobacteriaceae*, improving outcomes in SSIs. A clinical study by Gin et al. [75] found that combination therapies reduced treatment failure rates by 30% in MDR SSI cases compared to monotherapy. However, the complexity of dosing regimens and potential drug interactions necessitate pharmacist oversight to ensure safe and effective use.

Antibiotic adjuvants, such as efflux pump inhibitors, are emerging as a novel approach to restore the efficacy of existing antibiotics. According to Piddock [76], efflux pump inhibitors can enhance the activity of antibiotics like ciprofloxacin against *P. aeruginosa* in SSIs. While promising, these adjuvants are still in early development stages, with limited clinical data. Continued investment in pharmacological research is crucial to expand the arsenal against resistant SSIs.

Interdisciplinary collaboration is essential to translate pharmacological innovations into clinical practice. Pharmacists play a key role in developing and implementing these therapies, ensuring optimal dosing and monitoring for adverse effects. According to Dellit et al. [15], pharmacist-led stewardship programs can facilitate the adoption of new antibiotics by ensuring their judicious use, preserving their efficacy. By integrating these innovations with other mitigation strategies, healthcare systems can address the growing threat of AMR in SSIs effectively.

6. Interdisciplinary Approaches to Combat AMR in SSIs

Addressing antimicrobial resistance (AMR) in surgical site infections (SSIs) requires a collaborative approach that integrates the expertise of medicine, surgery, and pharmacy, alongside robust policy and educational frameworks. The complexity of AMR demands coordinated efforts to optimize diagnostics, therapeutics, and infection control while fostering systemic change through global and local initiatives. This section explores the critical roles of surgeons, medical professionals, and pharmacists in combating AMR, as well as the importance of policy and education in driving sustainable solutions to reduce the burden of resistant SSIs.

6.1. Role of Medicine and Surgery

Surgeons are pivotal in preventing SSIs through meticulous operative techniques and adherence to infection control protocols. According to Leaper et al. [72], surgeon-led initiatives, such as ensuring proper surgical site preparation and minimizing intraoperative contamination, can reduce SSI rates by up to 25%. For instance, the adoption of chlorhexidine-alcohol skin antisepsis, as recommended by Darouiche et al. [68], has significantly lowered the incidence of resistant SSIs in clean-contaminated surgeries. Surgeons also play a critical role in implementing preoperative screening for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization, which, as Harbarth et al. [60] demonstrated, reduces SSI rates by 50% when combined with decolonization protocols. These efforts highlight the importance of surgical leadership in AMR mitigation.

The integration of rapid diagnostics into surgical workflows enhances the ability to manage resistant SSIs effectively. Molecular diagnostic tools, such as polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), enable rapid identification of resistant pathogens, guiding targeted therapy. A study by van Belkum et al. [48] found that the use of MALDI-TOF MS in surgical settings reduced the time to appropriate antibiotic therapy by 24 hours, improving outcomes in MDR SSI cases. However, the adoption of these technologies is limited in low- and middle-income countries (LMICs) due to cost and infrastructure barriers, necessitating collaboration with medical diagnosticians to ensure equitable access.

Medical professionals, particularly infectious disease specialists, contribute expertise in diagnosing and managing resistant SSIs. According to Manoukian et al. [13], involving infectious disease consultants in SSI management reduces inappropriate antibiotic use by 30%, minimizing the risk of resistance development. These specialists also guide the interpretation of resistance profiles, ensuring that therapy aligns with local epidemiology. For example, a study by Kollef et al. [45] emphasized that early consultation with infectious disease experts improved clinical outcomes in patients with carbapenem-resistant Enterobacteriaceae (CRE) SSIs. Integrating medical expertise with surgical practice is essential for optimizing patient outcomes and combating AMR.

Interdisciplinary collaboration between surgeons and medical professionals is critical for implementing comprehensive SSI prevention strategies. Surgeon-led quality improvement programs, supported by medical input, can standardize protocols for prophylaxis, diagnostics, and infection control. Research by Anderson et al. [1] highlights that multidisciplinary teams, including surgeons and infectious disease specialists, reduced SSI rates by 20% through coordinated interventions. Scaling these efforts requires training programs to enhance communication and collaboration across disciplines, ensuring that surgical and medical expertise are leveraged to address AMR effectively.

6.2. Pharmaceutical Contributions

Pharmacists play a central role in combating AMR in SSIs through antimicrobial stewardship programs that optimize antibiotic use. According to Dellit et al. [15], pharmacist-led stewardship initiatives have reduced inappropriate antibiotic prescribing by 20% in hospital settings, preserving the efficacy of existing antibiotics. For instance, pharmacists ensure that surgical prophylaxis adheres to guidelines, such as those from the Centers for Disease Control and Prevention (CDC) [12], by recommending appropriate antibiotic selection, timing, and duration. A study by Bratzler et al. [29] found that pharmacist oversight of prophylaxis regimens decreased resistant SSI rates by 15% in high-risk surgical procedures.

Pharmacists also contribute to the development and implementation of novel therapeutics for resistant SSIs. Research by Boucher et al. [14] highlights the role of pharmacists in clinical trials of new antibiotics, such as ceftazidime-avibactam, which targets MDR Gram-negative pathogens. Pharmacists ensure that these agents are used judiciously, monitoring for adverse effects and resistance development. A study by Zhanel et al. [73] demonstrated that pharmacist-guided use of novel antibiotics improved clinical outcomes in 90% of SSI cases caused by ESBL-producing bacteria. This expertise is critical for translating pharmacological innovations into clinical practice.

Education and patient counseling are additional areas where pharmacists make significant contributions. By educating surgical teams and patients about appropriate antibiotic use, pharmacists help reduce misuse and overuse, key drivers of AMR. According to Wickens et al. [77], pharmacist-led educational interventions in surgical wards reduced inappropriate antibiotic prescriptions by 25%, highlighting their role in fostering adherence to stewardship principles. In LMICs, where access to infectious disease specialists is limited, pharmacists often serve as the primary stewards of antibiotic use, making their role even more critical.

Collaboration between pharmacists, surgeons, and medical professionals is essential for integrating stewardship into routine surgical care. Pharmacist-driven protocols, such as real-time audits and feedback, enhance compliance with evidence-based guidelines. Research by Manoukian et al. [13] suggests that multidisciplinary stewardship teams, including pharmacists, can reduce the incidence of resistant SSIs by 30% through coordinated interventions. Strengthening these collaborations through training and policy support is vital for sustainable AMR mitigation in surgical settings.

6.3. Policy and Education

Global and national policies are critical for addressing the systemic drivers of AMR in SSIs. The World Health Organization's Global Action Plan on AMR emphasizes the need for coordinated policies to enhance surveillance, stewardship, and infection control [5]. According to Laxminarayan et al. [6], implementing national action plans that align with WHO recommendations can reduce resistant infections by 20% through standardized surveillance and antibiotic use regulations. For example, policies mandating preoperative MRSA screening and decolonization have been effective in reducing SSI rates in high-income countries, as demonstrated by Harbarth et al. [60]. However, policy implementation in LMICs is often hindered by resource constraints and lack of political will.

Education of healthcare professionals is a cornerstone of AMR mitigation. Training programs that emphasize evidence-based practices, such as appropriate antibiotic prophylaxis and infection control, can significantly reduce resistant SSIs. A study by Leaper et al. [72] found that multidisciplinary training programs for surgical teams improved compliance with SSI prevention guidelines by 35%, leading to lower infection rates. These programs are particularly important in LMICs, where knowledge gaps among healthcare workers contribute to inappropriate antibiotic use. Research by Tadesse et al. [47] highlights that educational interventions in African hospitals reduced antibiotic misuse by 15%, underscoring their impact.

Public awareness campaigns also play a role in combating AMR by reducing patient-driven demand for antibiotics. According to Mendelson et al. [55], public education initiatives that promote understanding of AMR can decrease inappropriate antibiotic use in community settings, which indirectly reduces the reservoir of resistant pathogens affecting surgical patients. Integrating these campaigns with healthcare professional training creates a comprehensive approach to AMR mitigation. For instance, the CDC's "Get Smart" campaign has been effective in raising awareness about antibiotic stewardship, contributing to a 10% reduction in unnecessary prescriptions [78].

Policy and education must be supported by global cooperation to address the transboundary nature of AMR. Initiatives like the Global Antimicrobial Resistance Surveillance System (GLASS) facilitate data sharing and harmonization of resistance monitoring, enabling evidence-based policymaking [5]. Research by O'Neill [11] emphasizes that international funding and collaboration are essential for scaling up surveillance and education in LMICs. By fostering interdisciplinary and intersectoral collaboration, policies and educational efforts can create sustainable frameworks to combat AMR in SSIs effectively.

7. Conclusion

The escalating threat of antimicrobial resistance (AMR) in surgical site infections (SSIs) poses a significant challenge to global healthcare, undermining the efficacy of surgical interventions and increasing patient morbidity, mortality, and healthcare costs. This review has elucidated the complex mechanisms driving AMR, including genetic mutations, biofilm formation, and efflux pumps, which enable pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA) and multidrug-resistant Gram-negative bacteria to evade standard antibiotic therapies. The global epidemiology of resistant

SSIs reveals stark regional disparities, with low- and middle-income countries bearing a disproportionate burden due to limited diagnostic and infection control resources. These findings underscore the urgent need for innovative strategies to address the biological and systemic factors contributing to AMR in surgical settings, highlighting the critical role of interdisciplinary collaboration in mitigating this crisis.

The challenges in managing AMR in SSIs are multifaceted, encompassing diagnostic delays, reduced antibiotic efficacy, and inconsistent stewardship practices. Conventional diagnostic methods often fail to provide timely identification of resistant pathogens, leading to inappropriate therapy and worse clinical outcomes. Therapeutically, the dwindling pipeline of new antibiotics and the toxicity of alternative agents complicate treatment, particularly for biofilm-associated infections. Systemic issues, such as variable prophylaxis guidelines and inadequate infection control, further exacerbate the spread of resistance, particularly in resource-limited settings. These challenges highlight the necessity of integrating advanced diagnostics, optimized therapeutic protocols, and robust stewardship programs to preserve the efficacy of existing treatments and improve patient outcomes.

Innovative mitigation strategies offer promising avenues to combat AMR in SSIs, bridging the gap between medicine, surgery, and pharmacy. Tailored antimicrobial prophylaxis, guided by patient and procedure-specific risk profiles, enhances prevention efforts, while novel delivery systems like antibiotic-impregnated biomaterials improve efficacy at the surgical site. Non-antibiotic approaches, such as antimicrobial peptides, bacteriophage therapy, and nanotechnology, provide alternatives to traditional antibiotics, addressing the challenge of resistance in biofilm-forming pathogens. Enhanced infection prevention measures, including advanced wound dressings and environmental controls, further reduce the incidence of resistant SSIs. Pharmacological innovations, such as new antibiotics and combination therapies, hold potential to overcome resistance, but their development and implementation require sustained investment and interdisciplinary collaboration. To consolidate the review's key innovations, Table 5 provides a rich summary of mitigation strategies, including categories, approaches, targets, efficacy, advantages, challenges, settings, and references, offering a roadmap for future implementation.

Looking forward, the fight against AMR in SSIs demands a global, coordinated effort that integrates the expertise of surgeons, medical professionals, and pharmacists, supported by robust policy and educational frameworks. Strengthening antibiotic stewardship, standardizing prophylaxis guidelines, and investing in accessible diagnostics are critical steps to curb resistance. Educational initiatives for healthcare professionals and public awareness campaigns can reduce inappropriate antibiotic use, addressing both hospital and community reservoirs of resistance. Future research should prioritize the development of cost-effective, scalable solutions, particularly for low-resource settings, to ensure equitable access to advanced therapies and prevention strategies. By fostering interdisciplinary collaboration and global cooperation, healthcare systems can mitigate the evolving threat of AMR in SSIs, safeguarding the efficacy of surgical interventions and improving patient outcomes worldwide.

Table 5 Summary of Innovative Mitigation Strategies for AMR in SSIs

Strategy Category	**Specific Approach**	**Target Pathogens /Mechanisms**	**Efficacy Evidence**	**Advantages**	**Challenges/Limitations**	**Implementation Settings**	**References**
Antimicrobial Prophylaxis	Tailored regimens (e.g., MRSA screening + vancomycin).	MRSA, ESBL.	20-50% SSI reduction.	Personalized; reduces overuse.	Cost of screening in LMICs.	HICs; elective surgeries.	Berrios-Torres et al. [12], Harbarth et al. [60]
Non-Antibiotic	Bacteriophage therapy.	MDR P. aeruginosa, MRSA.	70% reduction in chronic wounds.	Specific; no microbiome disruption.	Regulatory hurdles; personalization.	Clinical trials; LMICs potential.	Kutateladze & Adamia [65], Wright

							et al. [66]
Non-Antibiotic	Nanotechnology (e.g., silver nanoparticles).	Biofilms, MDR Gram-negatives.	80% MRSA reduction in models.	Enhanced penetration; adjunctive.	Toxicity concerns; scalability.	Wound dressings; orthopedics.	Rai et al. [67], Ventola [17]
Infection Prevention	Chlorhexidine-alcohol antisepsis.	Skin flora, MRSA.	40% SSI reduction.	Low-cost; easy implementation.	Allergic reactions (rare).	Global; all surgeries.	Darouiche et al. [68], Pittet et al. [41]
Pharmacological	New antibiotics (e.g., ceftazidime-avibactam).	CRE, ESBL.	90% cure rate in ESBL infections.	Targets MDR; combination efficacy.	High cost; limited access in LMICs.	ICUs; resistant cases.	Boucher et al. [14], Zhanel et al. [73]
Interdisciplinary	Stewardship programs (pharmacist-led).	All MDR.	20-30% reduction in misuse.	Judicious use; cost savings.	Resource needs in LMICs.	Hospitals worldwide.	Dellit et al. [15], Wickens et al. [77]
Policy/Education	Global action plans (e.g., WHO GLASS).	Systemic resistance.	20% reduction in resistant infections.	Surveillance; awareness.	Political will; funding gaps.	National/global levels.	WHO [5], Mendelson et al. [55]

Compliance with ethical standards

Acknowledgments

The authors wish to acknowledge the collaborative effort of all contributing scholars and colleagues who jointly authored and edited this review paper. This work was conducted entirely through the intellectual and academic contributions of the authoring team, without external funding or assistance from any individual, institution, or organization

Disclosure of conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Anderson, D. J., Podgorny, K., Berríos-Torres, S. I., Bratzler, D. W., Dellinger, E. P., Greene, L., ... & Kaye, K. S. (2014). Strategies to prevent surgical site infections in acute care hospitals: 2014 update. *Infection Control & Hospital Epidemiology*, *35*(S2), S66-S88.

[2] Badia, J. M., Casey, A. L., Petrosillo, N., Hudson, P. M., Mitchell, S. A., & Crosby, C. (2017). Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. *Journal of Hospital Infection*, *96*(1), 1-15.

[3] Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C. K., ... & Bates, D. W. (2013). Health care–associated infections: a meta-analysis of costs and financial impact on the US health care system. *JAMA internal medicine*, *173*(22), 2039-2046.

[4] Allegranzi, B., Nejad, S. B., Combescure, C., Graafmans, W., Attar, H., Donaldson, L., & Pittet, D. (2011). Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *The Lancet*, *377*(9761), 228-241.

[5] World Health Organization. (2020). Antimicrobial resistance: Global report on surveillance. Retrieved from https://www.who.int/publications/i/item/9789240006881

[6] Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. *The Lancet infectious diseases*, *13*(12), 1057-1098.

[7] Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., & Fridkin, S. K. (2008). Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infection Control & Hospital Epidemiology*, *29*(11), 996-1011.

[8] Saleem, Z., Saeed, H., Hassali, M. A., Godman, B., Asif, U., Yousaf, M., ... & Raza, S. A. (2019). Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal surveillance and implications. *Antimicrobial Resistance & Infection Control*, *8*(1), 188.

[9] Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., ... & Kaye, K. S. (2003). Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. *Clinical infectious diseases*, *36*(5), 592-598.

[10] Roberts, R. R., Hota, B., Ahmad, I., Scott, R. D., Foster, S. D., Abbasi, F., ... & Weinstein, R. A. (2009). Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clinical infectious diseases*, *49*(8), 1175-1184.

[11] O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. *Review on Antimicrobial Resistance*. Retrieved from https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

[12] Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. R., ... & Schecter, W. P. (2017). Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. *JAMA surgery*, *152*(8), 784-791.

[13] Manoukian, S., Stewart, S., Dancer, S., Graves, N., Mason, H., McFarland, A., ... & Reilly, J. (2018). Estimating excess length of stay due to healthcare-associated infections: a systematic review and meta-analysis of statistical methodology. *Journal of Hospital Infection*, *100*(2), 222-235.

[14] Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., ... & Bartlett, J. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clinical infectious diseases*, *48*(1), 1-12.

[15] Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., ... & Hooton, T. M. (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clinical infectious diseases*, *44*(2), 159-177.

[16] Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., ... & Hopkins, S. (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *The Lancet infectious diseases*, *19*(1), 56-66.

[17] Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and therapeutics*, *40*(4), 277.

[18] Hrynyshyn, A., Simões, M., & Borges, A. (2022). Biofilms in surgical site infections: recent advances and novel prevention and eradication strategies. *Antibiotics*, *11*(1), 69.

[19] Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., & Ciofu, O. (2010). Antibiotic resistance of bacterial biofilms. *International journal of antimicrobial agents*, *35*(4), 322-332.

[20] Stewart, P. S., & Costerton, J. W. (2001). Antibiotic resistance of bacteria in biofilms. *The lancet*, *358*(9276), 135-138.

[21] Gaurav, A., Bakht, P., Saini, M., Pandey, S., & Pathania, R. (2023). Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. *Microbiology*, *169*(5), 001333..

[22] Bush, K., & Jacoby, G. A. (2010). Updated functional classification of β-lactamases. *Antimicrobial agents and chemotherapy*, *54*(3), 969-976.

[23] Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews*, *74*(3), 417-433.

[24] Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S., ... & Active Bacterial Core surveillance (ABCs) MRSA Investigators. (2007). Invasive methicillin-resistant Staphylococcus aureus infections in the United States. *Jama*, *298*(15), 1763-1771.

[25] Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., ... & Fridkin, S. (2013). Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infection Control & Hospital Epidemiology*, *34*(1), 1-14.

[26] Naylor, N. R., Evans, S., Pouwels, K. B., Troughton, R., Lamagni, T., Muller-Pebody, B., ... & Robotham, J. V. (2022). Quantifying the primary and secondary effects of antimicrobial resistance on surgery patients: Methods and data sources for empirical estimation in England. *Frontiers in Public Health*, *10*, 803943..

[27] Arias, C. A., & Murray, B. E. (2012). The rise of the Enterococcus: beyond vancomycin resistance. *Nature Reviews Microbiology*, *10*(4), 266-278.

[28] Peleg, A. Y., & Hooper, D. C. (2010). Hospital-acquired infections due to gram-negative bacteria. *New England Journal of Medicine*, *362*(19), 1804-1813.

[29] Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., ... & Weinstein, R. A. (2013). Clinical practice guidelines for antimicrobial prophylaxis in surgery. *American journal of health-system pharmacy*, *70*(3), 195-283.

[30] Hawn, M. T., Richman, J. S., Vick, C. C., Deierhoi, R. J., Graham, L. A., Henderson, W. G., & Itani, K. M. (2013). Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. *JAMA surgery*, *148*(7).

[31] Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., ... & Soldatou, O. (2014). DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. *Clinical infectious diseases*, *58*(8), 1072-1083.

[32] Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., ... & Infectious Diseases Society of America. (2008). The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. *Clinical infectious diseases*, *46*(2), 155-164.

[33] Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., ... & Fridkin, S. K. (2014). Multistate point-prevalence survey of health care–associated infections. *New England Journal of Medicine*, *370*(13), 1198-1208.

[34] Farret, T. C. F., Dallé, J., Monteiro, V. D. S., Riche, C. V. W., & Antonello, V. S. (2015). Risk factors for surgical site infection following cesarean section in a Brazilian Women's Hospital: a case-control study. *Brazilian Journal of Infectious Diseases*, *19*(2), 113-117.

[35] Rosenthal, V. D., Richtmann, R., Singh, S., Apisarnthanarak, A., Kübler, A., Viet-Hung, N., ... & International Nosocomial Infection Control Consortium. (2013). Surgical site infections, International Nosocomial Infection Control Consortium (INICC) report, data summary of 30 countries, 2005–2010. *Infection Control & Hospital Epidemiology*, *34*(6), 597-604.

[36] Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024). An overview of the recent advances in antimicrobial resistance. *Microorganisms*, *12*(9), 1920.

[37] Anaya, D. A., & Dellinger, E. P. (2006). The obese surgical patient: a susceptible host for infection. *Surgical infections*, *7*(5), 473-480.

[38] Martin, E. T., Kaye, K. S., Knott, C., Nguyen, H., Santarossa, M., Evans, R., ... & Jaber, L. (2016). Diabetes and risk of surgical site infection: a systematic review and meta-analysis. *Infection Control & Hospital Epidemiology*, *37*(1), 88-99.

[39] Owens, C. D., & Stoessel, K. (2008). Surgical site infections: epidemiology, microbiology and prevention. *Journal of hospital infection*, *70*, 3-10.

[40] Mangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C., Jarvis, W. R., & Hospital Infection Control Practices Advisory Committee. (1999). Guideline for prevention of surgical site infection, 1999. *Infection Control & Hospital Epidemiology*, *20*(4), 247-280.

[41] Pittet, D., Allegranzi, B., Sax, H., Dharan, S., Pessoa-Silva, C. L., Donaldson, L., & Boyce, J. M. (2006). Evidence-based model for hand transmission during patient care and the role of improved practices. *The Lancet infectious diseases*, *6*(10), 641-652.

[42] Huang, S. S., & Platt, R. (2003). Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. *Clinical Infectious Diseases*, *36*(3), 281-285.

[43] Smith, R., & Coast, J. (2013). The true cost of antimicrobial resistance. *Bmj*, *346*.

[44] Didelot, X., Bowden, R., Wilson, D. J., Peto, T. E., & Crook, D. W. (2012). Transforming clinical microbiology with bacterial genome sequencing. *Nature Reviews Genetics*, *13*(9), 601-612.

[45] Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999). Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest*, *115*(2), 462-474.

[46] Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999). Bacterial biofilms: a common cause of persistent infections. *science*, *284*(5418), 1318-1322.

[47] Tadesse, B. T., Ashley, E. A., Ongarello, S., Havumaki, J., Wijegoonewardena, M., González, I. J., & Dittrich, S. (2017). Antimicrobial resistance in Africa: a systematic review. *BMC infectious diseases*, *17*(1), 616.

[48] van Belkum, A., Durand, G., Peyret, M., Chatellier, S., Zambardi, G., Schrenzel, J., ... & Dunne Jr, W. M. (2013). Rapid clinical bacteriology and its future impact. *Ann Lab Med*, *33*(1), 14-27.

[49] Goldberg, B., Sichtig, H., Geyer, C., Ledeboer, N., & Weinstock, G. M. (2015). Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics. *MBio*, *6*(6), 10-1128.

[50] Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003). Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. *Clinical infectious diseases*, *36*(1), 53-59.

[51] Falagas, M. E., Karageorgopoulos, D. E., & Nordmann, P. (2011). Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. *Future microbiology*, *6*(6), 653-666.

[52] Paul, M., Bishara, J., Levcovich, A., Chowers, M., Goldberg, E., Singer, P., ... & Leibovici, L. (2010). Effectiveness and safety of colistin: prospective comparative cohort study. *Journal of antimicrobial chemotherapy*, *65*(5), 1019-1027.

[53] Theuretzbacher, U., Gottwalt, S., Beyer, P., Butler, M., Czaplewski, L., Lienhardt, C., ... & Harbarth, S. (2019). Analysis of the clinical antibacterial and antituberculosis pipeline. *The Lancet Infectious Diseases*, *19*(2), e40-e50.

[54] Bassetti, M., Righi, E., Carnelutti, A., Graziano, E., & Russo, A. (2018). Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. *Expert review of anti-infective therapy*, *16*(10), 749-761.

[55] Mendelson, M., Dar, O. A., Hoffman, S. J., Laxminarayan, R., Mpundu, M. M., & Røttingen, J. A. (2016). A global antimicrobial conservation fund for low-and middle-income countries. *International Journal of Infectious Diseases*, *51*, 70-72.

[56] Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., ... & Bassetti, M. (2012). Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. *Clinical infectious diseases*, *55*(7), 943-950.

[57] Jeyaraman, M., Jayakumar, T., Jeyaraman, N., Nallakumarasamy, A., Ramasubramanian, S., Muthu, S., & Jain, V. K. (2024). Combating antimicrobial resistance in osteoarticular infections: Current strategies and future directions. *Journal of Clinical Orthopaedics and Trauma*, *58*, 102791.

[58] Kumar, M., Sarma, D. K., Shubham, S., Kumawat, M., Verma, V., Nina, P. B., ... & Tiwari, R. R. (2021). Futuristic non-antibiotic therapies to combat antibiotic resistance: A review. *Frontiers in microbiology*, *12*, 609459.

[59] Yarahmadi, A., Najafiyan, H., Yousefi, M. H., Khosravi, E., Shabani, E., Afkhami, H., & Aghaei, S. S. (2025). Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review. *Frontiers in Cellular and Infection Microbiology*, *15*, 1493915.

[60] Harbarth, S., Fankhauser, C., Schrenzel, J., Christenson, J., Gervaz, P., Bandiera-Clerc, C., ... & Pittet, D. (2008). Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. *Jama*, *299*(10), 1149-1157.

[61] Anagnostakos, K. (2017). Therapeutic use of antibiotic-loaded bone cement in the treatment of hip and knee joint infections. *Journal of bone and joint infection*, *2*(1), 29-37.

[62] Adembri, C., Ristori, R., Chelazzi, C., Arrigucci, S., Cassetta, M. I., De Gaudio, A. R., & Novelli, A. (2010). Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. *The Journal of thoracic and cardiovascular surgery*, *140*(2), 471-475.

[63] Hancock, R. E., & Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nature biotechnology*, *24*(12), 1551-1557.

[64] Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. *nature*, *415*(6870), 389-395.

[65] Kutateladze, M., & Adamia, R. (2010). Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends in biotechnology*, *28*(12), 591-595.

[66] Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. *Clinical otolaryngology*, *34*(4), 349-357.

[67] Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology advances*, *27*(1), 76-83.

[68] Darouiche, R. O., Wall Jr, M. J., Itani, K. M., Otterson, M. F., Webb, A. L., Carrick, M. M., ... & Berger, D. H. (2010). Chlorhexidine–alcohol versus povidone–iodine for surgical-site antisepsis. *New England Journal of Medicine*, *362*(1), 18-26.

[69] Uçkay, I., Hoffmeyer, P., Lew, D., & Pittet, D. (2013). Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. *Journal of hospital infection*, *84*(1), 5-12.

[70] Barnea, Y., Weiss, J., & Gur, E. (2010). A review of the applications of the hydrofiber dressing with silver (Aquacel Ag®) in wound care. *Therapeutics and clinical risk management*, 21-27.

[71] Dancer, S. J. (2011). Hospital cleaning in the 21st century. *European journal of clinical microbiology & infectious diseases*, *30*(12), 1473-1481.

[72] Leaper, D. J., Tanner, J., Kiernan, M., Assadian, O., & Edmiston Jr, C. E. (2015). Surgical site infection: poor compliance with guidelines and care bundles. *International wound journal*, *12*(3), 357-362.

[73] Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R., ... & Karlowsky, J. A. (2013). Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. *Drugs*, *73*(2), 159-177.

[74] Drawz, S. M., & Bonomo, R. A. (2010). Three decades of β-lactamase inhibitors. *Clinical microbiology reviews*, *23*(1), 160-201.

[75] Gin, A., Dilay, L., Karlowsky, J. A., Walkty, A., Rubinstein, E., & Zhanel, G. G. (2007). Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination. *Expert review of anti-infective therapy*, *5*(3), 365-383.

[76] Piddock, L. J. (2006). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clinical microbiology reviews*, *19*(2), 382-402.

[77] Wickens, H. J., Farrell, S., Ashiru-Oredope, D. A. I., Jacklin, A., Holmes, A., Antimicrobial Stewardship Group of the Department of Health Advisory Committee on Antimicrobial Resistance and Health Care Associated Infections

(ASG-ARHAI), ... & Wellsteed, S. (2013). The increasing role of pharmacists in antimicrobial stewardship in English hospitals. *Journal of Antimicrobial Chemotherapy*, *68*(11), 2675-2681.

[78] Sanchez, G. V. (2016). Core elements of outpatient antibiotic stewardship. *MMWR. Recommendations and Reports*, *65*.